8-K

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Dateof Report (Date of earliest event reported): August 1, 2025

IMACHoldings, Inc.

(Exactname of registrant as specified in its charter)

Delaware	001-38797	83-0784691
(State or other jurisdiction of<br><br> <br>incorporation or organization)	(Commission<br><br> <br>File Number)	(I.R.S. Employer<br><br> <br>Identification Number)
3401 Mallory Lane, Suite 100<br><br> <br>Franklin, Tennessee	37067
---	---
(Address of principal executive offices)	(Zip Code)

Registrant’stelephone number, including area code: (844) 266-4622

(Formername or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications<br> pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant<br> to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications<br> pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications<br> pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	BACK	OTC Markets Group, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item1.01 Entry into a Material Definitive Agreement.

The information provided in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

On August 1, 2025, Ignite Proteomics, LLC, a wholly owned subsidiary of IMAC Holdings, Inc. (the “Company”), entered into a one-year Research Collaboration Agreement (the “Agreement”) with Vanderbilt University Medical Center (“VUMC”). Under the Agreement, VUMC will supply up to 80 de-identified FFPE breast-cancer samples and Ignite will perform reverse phase protein array (RPPA) analysis of priority tumor-immune biomarkers. Each party will bear its own costs. Ignite receives an exclusive, time-bounded option to negotiate a worldwide license to jointly develop intellectual property. The Agreement may be terminated on 30 days’ notice by either party. A copy of the Agreement is filed as Exhibit 10.1 to this Current Report.

Item2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On August 5, 2025, IMAC Holdings, Inc. (the “Company”) issued a promissory note (the “Note”) to a certain lender (the “Lender”) in the aggregate principal amount of $84,000 for an aggregate purchase price from the Lenders of $60,000.

The Note is unsecured and matures on December 24, 2025. The Company may prepay any portion of the outstanding principal at any time without penalty.

The Note includes customary representations, warranties and covenants and sets forth certain events of default after which the outstanding principal may be declared immediately due and payable, including certain types of bankruptcy or insolvency events of default involving the Company.

The foregoing description of the Note is not complete and is qualified in its entirety by reference to the full text of the Note, a copy of the form of which is filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 6, 2025 and is incorporated herein by reference.

Item7.01 Regulation FD Disclosure

On August 7, 2025, the Company issued a press release announcing the collaboration, a copy of which is furnished as Exhibit 99.1 to this Current Report.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
4.1	Form of Promissory Note (filed as Exhibit 4.1 to the Company’s Form 8-K filed with the SEC on May 6, 2025 and incorporated herein by reference).
10.1	Research Collaboration Agreement between Ignite Proteomics, LLC and Vanderbilt University Medical Center dated August 1, 2025 (certain portions redacted).
99.1	Press Release dated August 7,<br> 2025.
104	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 7, 2025

IMAC HOLDINGS, INC.
By:	/s/ Faith Zaslavsky
Name:	Faith Zaslavsky
Title:	Chief Executive Officer

Exhibit 10.1

Exhibit99.1

IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery

Project will leverage Ignite Proteomics’ reverse-phase protein array (RPPA) platform to profile tumor-immune signaling in breast-cancer samples

Golden, CO – August 7, 2025

Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB: BACK), today announced a one-year research collaboration with Vanderbilt University Medical Center (VUMC) to characterize protein-signaling pathways that help breast-tumor cells evade the immune system. Under the agreement, VUMC will provide de-identified formalin-fixed, paraffin-embedded (FFPE) tumor tissue from patients undergoing standard of care chemotherapy and immunotherapy, while Ignite will perform laser-capture micro-dissection and high-throughput RPPA analysis of priority immune and signaling biomarkers, including validation of those previously shown to be beneficial in identifying patients who need immunotherapy to achieve a cure.

“Partnering with VUMC’s world-class immuno-oncology team allows us to deploy our RPPA platform on rigorously annotated clinical samples,” said Faith Zaslavsky, President and Chief Executive Officer of Ignite Proteomics. “By quantifying many immune-checkpoint and signaling proteins simultaneously, we aim to illuminate mechanisms of response and resistance that genomic and single protein tests alone cannot capture.”

Dr. Justin Balko, Pharm.D., Ph.D., Principal Investigator at VUMC, added: “This collaborative study gives us a unique window into tumor–immune interactions in breast cancer. Ignite’s pathway-level protein read-outs should accelerate our search for actionable biomarkers that can refine immunotherapy strategies and combination regimens.”

Key terms of the collaboration

●	Scope:<br> RPPA profiling of up to 80 FFPE tumor specimens covering priority targets such as MHC-I/II,<br> PD-L1, AKT/mTOR, EGFR/HER2, and additional phospho-signaling nodes.
●	Structure:<br> Each party funds its own work; Ignite’s contribution is in-kind assay support.
---	---
●	Timeline:<br> Initial data packages are expected within 2 months of sample receipt.
---	---
●	Intellectual-property<br> option: Ignite receives a first right to negotiate an exclusive license to any jointly developed<br> IP.
---	---

About Immunotherapies

Immune-checkpoint blockade - led by pembrolizumab (Keytruda) and peer PD-1/PD-L1 or CTLA-4 antibodies - has transformed modern oncology, achieving durable responses across more than two dozen tumor types. Yet objective response rates still hover below 40 percent and resistance frequently emerges, underscoring the limitations of single-analyte tests such as PD-L1 IHC. Multi-dimensional biomarker platforms - integrating pathway-level protein, genomic and micro-environment data - are therefore essential to match immunotherapies to the patients most likely to benefit and to deliver these life-extending drugs earlier in the treatment journey.

About Ignite Proteomics

Ignite Proteomics, a subsidiary of IMAC Holdings, delivers pathway-level protein analytics to guide precision oncology. Operating a CLIA-certified, CAP-accredited laboratory, Ignite’s clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from minute biopsy material, with many more in research stages, enabling oncologists and drug developers to match patients with the most effective targeted and immune therapies.

About Vanderbilt University Medical Center

Vanderbilt University Medical Center, based in Nashville, Tennessee, is a global leader in academic medicine, research, and patient care, hosting more than two million patient visits each year and maintaining one of the nation’s largest programs in cancer research and treatment.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the expected scope, timeline, and potential outcomes of the collaboration with VUMC. Forward-looking statements are based on current assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Important factors that could affect actual results include, among others, the successful completion of the research project, the validity and reproducibility of study data, regulatory developments, and the ability of the parties to negotiate any future license agreement. Except as required by law, IMAC Holdings undertakes no obligation to update forward-looking statements contained herein to reflect events or circumstances after the date of this release.

Investor & Media Contact

investors@imacholdings.com

| www.igniteproteomics.com